Affinity CP

2020: Treatment of COVID-19

At the beginning of June, 2020 Medtronic temporarily changed indications to use of several devices that doctors could use technology of extracorporal membrane oxygenation (ECMO) for treatment of people with hard cases of COVID-19.

ECMO can call technology of "artificial lungs" which pumps over blood from a body of the person in an oksigenator, deletes a carbon dioxide gas and hemoglobin oxygenates. Structures of Medtronic got permission of the regulator earlier and were used as extracorporal support within 6 hours. This time was considered as maximum allowed for the procedures of artificial blood circulation provided with devices of this type.

Medtronic released "artificial lungs" for treatment of COVID-19

Medtronic discussed a problem of shortage of the equipment for heavy patients with a koronavirusny infection with the regulator. They came to a conclusion that the following ECMO devices can be used within 6 hours and more for treatment of people from sharp respiratory / serdechno-legochnoy by insufficiency during COVID-19 pandemic:

• The pump console for extracorporal oxygenation of Bio-Console 560 with additions;
• Affinity CP adapter;
• The centrifugal pump for Affinity blood forcing.

The ECMO technology can help with fight against COVID-19 because it potentially reduces or eliminates need for artificial ventilation of lungs. The Fresenius Medical Care company also recognized perspectives of this technology and announced expansion of production of the ECMO Novalung systems. Models of this system went to Wuhan in February. The regulator allowed to change temporarily indications to Novalung application to provide extracorporal support of patients more than six hours in a row. Fresenius already began deliveries of the new version of the device to hospitals of the USA.^[1]

Notes